Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Dosimetric comparison of proton therapy and CyberKnife in stereotactic body radiation therapy for liver cancers.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Additional Information
- Source:
Publisher: Springer Country of Publication: Switzerland NLM ID: 101760671 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2662-4737 (Electronic) Linking ISSN: 26624729 NLM ISO Abbreviation: Phys Eng Sci Med Subsets: MEDLINE
- Publication Information:
Original Publication: Switzerland : Springer, [2020]-
- Subject Terms:
- Abstract:
Stereotactic body radiation therapy (SBRT) has been increasingly used for the ablation of liver tumours. CyberKnife and proton beam therapy (PBT) are two advanced treatment technologies suitable to deliver SBRT with high dose conformity and steep dose gradients. However, there is very limited data comparing the dosimetric characteristics of CyberKnife to PBT for liver SBRT. PBT and CyberKnife plans were retrospectively generated using 4DCT datasets of ten patients who were previously treated for hepatocellular carcinoma (HCC, N = 5) and liver metastasis (N = 5). Dose volume histogram data was assessed and compared against selected criteria; given a dose prescription of 54 Gy in 3 fractions for liver metastases and 45 Gy in 3 fractions for HCC, with previously published consensus-based normal tissue dose constraints. Comparison of evaluation parameters showed a statistically significant difference for target volume coverage and liver, lungs and spinal cord (p < 0.05) dose, while chest wall and skin did not indicate a significant difference between the two modalities. A number of optimal normal tissue constraints was violated by both the CyberKnife and proton plans for the same patients due to proximity of tumour to chest wall. PBT resulted in greater organ sparing, the extent of which was mainly dependent on tumour location. Tumours located on the liver periphery experienced the largest increase in organ sparing. Organ sparing for CyberKnife was comparable with PBT for small target volumes.
(© 2024. The Author(s).)
- References:
Radiol Med. 2022 Feb;127(2):214-219. (PMID: 35034325)
Cancers (Basel). 2022 Jul 18;14(14):. (PMID: 35884538)
Radiother Oncol. 2021 Dec;165:1-7. (PMID: 34648871)
BMC Cancer. 2010 Sep 03;10:475. (PMID: 20813065)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
Onco Targets Ther. 2016 Nov 18;9:7169-7175. (PMID: 27920555)
Clin Transl Oncol. 2016 Nov;18(11):1158-1159. (PMID: 27686231)
Radiat Oncol. 2006 Dec 16;1:46. (PMID: 17173702)
Onco Targets Ther. 2014 Jun 12;7:915-23. (PMID: 24959080)
Rep Pract Oncol Radiother. 2021 Feb 25;26(1):66-72. (PMID: 33948304)
Rep Pract Oncol Radiother. 2020 May-Jun;25(3):299-306. (PMID: 32194349)
Cureus. 2017 Sep 10;9(9):e1674. (PMID: 29152431)
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820904447. (PMID: 32336255)
Anticancer Res. 2021 Mar;41(3):1529-1538. (PMID: 33788746)
Acta Oncol. 2011 Aug;50(6):823-8. (PMID: 21767180)
Phys Imaging Radiat Oncol. 2018 Nov 22;8:17-22. (PMID: 33458411)
Magn Reson Imaging. 2012 Nov;30(9):1323-41. (PMID: 22770690)
Phys Med Biol. 2018 Sep 21;63(19):195001. (PMID: 30183674)
Pract Radiat Oncol. 2015 Jul-Aug;5(4):209-18. (PMID: 25703530)
World J Hepatol. 2015 Jan 27;7(1):101-12. (PMID: 25625001)
Clin Oncol (R Coll Radiol). 2018 Jan;30(1):5-14. (PMID: 29033164)
Cancers (Basel). 2015 Jun 29;7(3):1143-53. (PMID: 26132317)
Med Phys. 2011 Jun;38(6):2914-36. (PMID: 21815366)
Clin Oncol (R Coll Radiol). 2020 Jul;32(7):459-466. (PMID: 32307206)
Clin Oncol (R Coll Radiol). 2018 May;30(5):285-292. (PMID: 29454504)
- Contributed Indexing:
Keywords: CyberKnife; Liver; Proton Therapy; Stereotactic radiotherapy; Treatment planning
- Publication Date:
Date Created: 20240529 Date Completed: 20240917 Latest Revision: 20240920
- Publication Date:
20240920
- Accession Number:
PMC11408538
- Accession Number:
10.1007/s13246-024-01440-x
- Accession Number:
38809365
No Comments.